Continuous low-dose cytokine infusion therapy

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 38/19 (2006.01) A61K 38/18 (2006.01) A61K 38/21 (2006.01) A61K 47/48 (2006.01)

Patent

CA 2236591

A method is provided for treating conditions that are susceptible of treatment with a cytokine wherein the undesirable side effects normally associated with cytokine administration are diminished or eliminated. The method comprises continuously administering a low dose of a cytokine to an individual afflicted with a condition susceptible of treatment with the cytokine. In a preferred embodiment of the invention, chronic hepatitis C is treated by administering a low dose amount of interferon.

Cette invention concerne un procédé de traitement de troubles susceptibles d'être traités avec une cytokine, ledit procédé permettant de réduire ou de supprimer les effets secondaires indésirables normalement associés à l'administration de cytokine. Ce procédé consiste à administrer de manière continue une faible dose d'une cytokine à un sujet atteint d'un trouble susceptible d'être traité par ladite cytokine. Selon une réalisation préférée de l'invention, on traite l'hépatite C chronique en administrant une faible dose d'interféron.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Continuous low-dose cytokine infusion therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Continuous low-dose cytokine infusion therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Continuous low-dose cytokine infusion therapy will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2084947

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.